Sanofi discontinues JAK-2 inhibitor in development for MF

Sanofi (Euronext:SAN; NYSE:SNY) discontinued development of fedratinib ( SAR302503), a selective oral Janus kinase-2 (JAK-2) inhibitor that was in Phase III testing for myeloproliferative disorders in...